NCT01293994|Withdrawn
Study Stopped
Do not have necessary resources to continue
Loading search results
Do not have necessary resources to continue
Sponsor study identifier
Secondary identifiers
OTHER · Stanford University Panel on Human Subjects
observational
0
1 country
1
Study Start
February 2009
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
December 2012
Actual (reported)Study Completion
December 2012
Actual (reported)The investigators will be collecting saliva DNA samples from chronic back pain patients. The investigators hope to find candidate genes associated with response to opioid medication by correlating molecular genetics data with pain measurement and opioid responsiveness data including opioid hyperalgesia and opioid analgesic tolerance.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2012
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 2009
Date type not reportedThis date has not been verified as actual or estimated.
February 9, 2011
Actual (reported)February 11, 2011
Actual (reported)December 2012
Actual (reported)December 2012
Actual (reported)Genetic association with various physiologic responses to opioid medication in patients
Up to 5 years
Any gender, ages 18-70, of any ethnic background
Stanford University School of Medicine
Stanford, California, 94305, United States
Saliva biospecimen collection will be performed via mail or in person. The PI will send participants a letter informing them of the opportunity to participate in a study of genetic variation influencing pain and opioid responsiveness phenotypes. If participants agree to provide a saliva biospecimen and to participate in the study, an informed consent letter and an Oragene™ DNA Self-Collection Kit, in disk format OG-250 (DNA Genotek, Inc., Ottawa, Ontario, Canada) will be sent to the participant by the PI. According to the manufacturer instructions, participants will provide a 2 ml saliva sample, which will be preserved using the reagents provided within the Oragene™ kit. Saliva samples are considered stable at room temperature for 5 years by Oragene™.
Dr Larry Fu-nien Chu
Stanford University
0 participants (actual enrollment reported by the registry).
First Submitted
February 9, 2011
First Posted
February 11, 2011
Study Start
February 2009
Date type not reportedThis date has not been verified as actual or estimated.
Effects of a Peripheral Nerve Block on Biomarkers of Pain and Inflammation
Contact the study team to confirm eligibility.
Primary Completion
December 2012
Actual (reported)Study Completion
December 2012
Actual (reported)Last Updated
November 22, 2016
Record last verified: 2016-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: